HY-P99115-5mg
|
MedChemexpress LLC
|
Envafolimab [CAS 2102192-68-5]
|
|
Cancer-programmed cell death
|
|
HY-P9984-1mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
HY-P9984-10mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
HY-P9984-5mg
|
MedChemexpress LLC
|
Etrolizumab [CAS 1044758-60-2]
|
|
Cancer-programmed cell death
|
|
HY-129937A-1mg
|
MedChemexpress LLC
|
GNE-987 [CAS 2417371-71-0]
|
|
Cancer-programmed cell death
|
|
HY-129937A-10mg
|
MedChemexpress LLC
|
GNE-987 [CAS 2417371-71-0]
|
|
Cancer-programmed cell death
|
|
HY-129937A-5mg
|
MedChemexpress LLC
|
GNE-987 [CAS 2417371-71-0]
|
|
Cancer-programmed cell death
|
|
HY-P99263-1mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99263-10mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-P99263-5mg
|
MedChemexpress LLC
|
Inclacumab [CAS 1256258-86-2]
|
|
Neuroscience-Neuromodulation
|
|
HY-112099-10mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-25mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-5mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-50mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|